T2	Procedure 10 24	pathologically
T3	Value 25 34	confirmed
R2	Has_value Arg1:T2 Arg2:T3	
T4	Condition 35 58	invasive adenocarcinoma
T5	Condition 62 86	ductal carcinoma in situ
*	OR T5 T4
R1	AND Arg1:T4 Arg2:T2	
R3	AND Arg1:T5 Arg2:T2	
T1	Procedure 132 152	segmental mastectomy
T6	Procedure 160 170	lumpectomy
R4	Subsumes Arg1:T1 Arg2:T6	
T7	Procedure 212 229	radiation therapy
T8	Negation 188 191	not
R5	Has_negation Arg1:T7 Arg2:T8	
T9	Qualifier 87 100	of the breast
R6	Has_qualifier Arg1:T4 Arg2:T9	
R7	Has_qualifier Arg1:T5 Arg2:T9	
T10	Condition 276 298	local-regional disease
T11	Undefined_semantics 276 298	local-regional disease
T12	Temporal 269 275	active
R8	Has_temporal Arg1:T10 Arg2:T12	
T13	Negation 260 263	not
R9	Has_negation Arg1:T10 Arg2:T13	
T14	Pregnancy_considerations 323 677	Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment. Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant. They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy.
T15	Post-eligibility 679 804	Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment.
T16	Post-eligibility 806 970	All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.
